Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05651373
Other study ID # RA with Pregnancy QiluH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 30, 2021
Est. completion date December 31, 2024

Study information

Verified date December 2022
Source Qilu Hospital of Shandong University
Contact Qiang Shu
Phone 0086-0531-82169654
Email shuqiang@sdu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study includes RA patients in pregnancy, who are using different treatment regimens,including prednisone, hydroxychloroquine, and/or TNF inhibitors. The maternal disease activity, pregnancy outcomes, maternal and fetal safety are assessing during the trimester of pregnancy. The effects of different therapies and risk factors for adverse pregnancy outcomes will be analysis.


Description:

To study the risk factors of poor pregnancy outcomes in RA patients, and evaluate impact of different therapies on the maternal and fetal health. The follow-up study will be scheduled every 4 weeks from confirmed pregnancy until delivery, records the disease activity of RA, pregnancy outcome and safety with the help of the "smart disease management system (SSDM)" and face-to-face consultations. The effects of different therapies on maternal and fetal will be valued


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: - 1.Age between 20 and 45 years old. 2.Diagnosis of RA: Approved by the American College of Rheumatology and the European League Against Rheumatism in 2010. Involved joints 1 large joint (0 points) 2-10 large joints (1 point) 1-3 small joints (with or without large joints) (2 points) 4-10 small joints (with or without large joints) (3 points) more than 10 small joints (at least one small joint) (5 points) Serological indicators RF and ACPA negative (0 points) RF and ACPA, at least one of which is low titer positive. (2 points) RF and ACPA with at least one high titer positive (3 points) Acute chronotropic reactants Both CRP and ESR normal (0 points) Abnormal CRP or ESR (1 point) Duration of synovitis <6 weeks (0 points) =6 weeks (1 point) 3.Voluntary participation in this study, willingness to administer medication and follow up according to the treatment plan, and signing of an informed consent form. Exclusion Criteria: - Women who meet any of the following criteria will be excluded from the study 1. Any known etiology of previous pregnancy loss 1. Known paternal, maternal or embryonic chromosomal abnormalities. 2. Maternal endocrine dysfunction: luteal insufficiency; polycystic ovary syndrome; premature ovarian failure (follicular phase stimulating hormone, FSH = 20uU/L). 3. Hyperprolactinemia; diabetes mellitus; other abnormalities of the hypothalamic pituitary-adrenal axis. 4. Maternal anatomical abnormalities: uterine malformations; Asherman syndrome; cervical insufficiency; uterine fibrosis greater than 5 cm. vaginal infection. 5. Any known serious cardiac, hepatic, renal, hematologic or endocrine disease. 2. Any active infection, including bacterial, alisla virus (VZV), human immunodeficiency virus (HIV), human papillomavirus (HPV), syphilis, tuberculosis, fungal infections, etc. 3. Hypersensitivity to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin 4. History of the following diseases. 1. Past history of peptic ulcer or upper gastrointestinal bleeding. 2. Past history of malignancy. 3. Past history of epilepsy or mental disorder. 4. Female has been diagnosed with SLE 5. Women who do not consent or are unable to complete pregnancy and postpartum follow-up.

Study Design


Intervention

Drug:
Prednisone
5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Hydroxychloroquine
200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
CertolizumabPegol injection
200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.

Locations

Country Name City State
China Qilu Hospital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of patients who achieve clinical remission using DAS28-CRP The percentage of patients whose DAS28 achieve remission(DAS28-CRP= 2.6)and Low Disease Activity (DAS28-CRP =3.2) . through study completion, an average of 10 months
Secondary Early fetal loss Spontaneous pregnancy loss within 10 weeks of gestation within 10 weeks of gestation
Secondary Late fetal loss Spontaneous pregnancy loss after 10 weeks of gestation after 10 weeks of gestation
Secondary Still birth Spontaneous pregnancy loss after 10 weeks of gestation. after 10 weeks of gestation
Secondary Preterm delivery Live birth before 37 weeks of gestation. between 28 and 37 weeks of gestation
Secondary Low-weight birth newborns with low weight (<2500g) after 28 weeks of gestation
Secondary Premature rupture of membranes the number of participants complicated with placental abruption after 28 weeks of gestation
Secondary Placental abruption the number of participants complicated with placental abruption after 28 weeks of gestation
Secondary Fetal growth retardation (FGR) weight below the 10th percentile for the gestational age after 12 weeks of gestation
Secondary Number of participants with low amniotic fluid during pregnancy the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy after 12 weeks of gestation
Secondary Number of participants with abnormal S / D values during pregnancy the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy after 12 weeks of gestation
Secondary Number of participants with placental hematoma during pregnancy the number of participants whose B-ultrasound indicates placental hematoma during pregnancy during pregnancy
Secondary Eclampsia New-onset hypertension after 20 weeks of gestation, with or without proteinuria > 300mg/24h, with or without any organ damage with seizures after 20 weeks of gestation
Secondary Gestational diabetes the number of participants who were diagnosed with gestational diabetes through study completion, an average of 10 months
Secondary Gestational hypertension the number of participants who were diagnosed with gestational hypertension through study completion, an average of 10 months
Secondary Number of participants with placental infarction the number of participants whose placenta with infarction. at delivery
Secondary Change From Baseline in C-reactive Protein (CRP) Change from Baseline in C-reactive Protein (CRP), CRP will be measured with blood samples. through study completion, an average of 10 months
Secondary Erythrocyte Sedimentation Rate (ESR) Change from Baseline in Erythrocyte Sedimentation Rate (ESR), ESR will be measured with blood samples. through study completion, an average of 10 months
Secondary Live birth rate Percentage of all patients that lead to live birth after 28 weeks of gestation After 28 weeks of gestation
Secondary Change from baseline Simplified Disease Activity Index (SDAI) SDAI score exceeding 26 is considered high disease activity; 11 through study completion, an average of 10 months
Secondary Change from baseline Clinical Disease Activity Index (CDAI) CDAI > 22 is considered high disease activity; 10 through study completion, an average of 10 months
Secondary swollen joint number (SW28) SW28 means the number of joints with swelling counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. through study completion, an average of 10 months
Secondary tenderness joint number (T28) T28 means the number of joints with tenderness upon touching counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. through study completion, an average of 10 months
Secondary patient global assessment(PGA) patient global assessment(PGA) through study completion, an average of 10 months
Secondary Health Assessment Questionnaire (HAQ) Health Assessment Questionnaire (HAQ) through study completion, an average of 10 months
Secondary Percentage of patients achieving Boolean remission Clinical remission was defined when the number of swollen joints =1, the number of painful joints =1, CRP =1 mg/dl and the patient's overall score of the disease =1 were also satisfied. through study completion, an average of 10 months
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4